AR084905A1 - Derivados de 2,3-dihidro-furo[2,3-c]piridina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por la activacion del receptor gpr119 acoplado a proteinas g - Google Patents

Derivados de 2,3-dihidro-furo[2,3-c]piridina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por la activacion del receptor gpr119 acoplado a proteinas g

Info

Publication number
AR084905A1
AR084905A1 ARP120100198A ARP120100198A AR084905A1 AR 084905 A1 AR084905 A1 AR 084905A1 AR P120100198 A ARP120100198 A AR P120100198A AR P120100198 A ARP120100198 A AR P120100198A AR 084905 A1 AR084905 A1 AR 084905A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
ring
independently
cycloalkyl
Prior art date
Application number
ARP120100198A
Other languages
English (en)
Spanish (es)
Inventor
Frank Himmelsbach
Elke Langkopf
Bernd Nosse
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR084905A1 publication Critical patent/AR084905A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP120100198A 2011-01-21 2012-01-20 Derivados de 2,3-dihidro-furo[2,3-c]piridina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por la activacion del receptor gpr119 acoplado a proteinas g AR084905A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11151688 2011-01-21
EP11191903 2011-12-05

Publications (1)

Publication Number Publication Date
AR084905A1 true AR084905A1 (es) 2013-07-10

Family

ID=45495952

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100198A AR084905A1 (es) 2011-01-21 2012-01-20 Derivados de 2,3-dihidro-furo[2,3-c]piridina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por la activacion del receptor gpr119 acoplado a proteinas g

Country Status (19)

Country Link
US (1) US8778926B2 (OSRAM)
EP (1) EP2665719B1 (OSRAM)
JP (1) JP5703393B2 (OSRAM)
KR (1) KR20140003496A (OSRAM)
CN (1) CN103443097A (OSRAM)
AP (1) AP2013006985A0 (OSRAM)
AR (1) AR084905A1 (OSRAM)
AU (1) AU2012208530A1 (OSRAM)
BR (1) BR112013017669A2 (OSRAM)
CA (1) CA2825124A1 (OSRAM)
CO (1) CO6781501A2 (OSRAM)
EA (1) EA201300846A1 (OSRAM)
EC (1) ECSP13012800A (OSRAM)
MA (1) MA34839B1 (OSRAM)
MX (1) MX2013008083A (OSRAM)
PH (1) PH12013501515A1 (OSRAM)
SG (1) SG192036A1 (OSRAM)
UY (1) UY33871A (OSRAM)
WO (1) WO2012098217A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2686312B1 (en) 2011-03-14 2016-08-31 Boehringer Ingelheim International GmbH N-cyclopropyl-n-piperidinylbenzamides as gpr119 modulators
EP2718288B1 (en) 2011-06-09 2015-03-11 Boehringer Ingelheim International GmbH Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders
US8853239B2 (en) 2011-12-09 2014-10-07 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US9012456B2 (en) * 2012-02-28 2015-04-21 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8809361B2 (en) * 2012-05-07 2014-08-19 Boehringer Ingelheim International Gmbh 2,3-dihydrofuro[2,3-c]pyridines, their use as modulators of the G-protein-coupled receptor GPR119 and pharmaceutical compositions thereof
US10208030B2 (en) 2016-04-08 2019-02-19 Mankind Pharma Ltd. GPR119 agonist compounds
US10526345B2 (en) 2016-04-08 2020-01-07 Mankind Pharma Ltd. Compounds as GPR119 agonists
US10954229B2 (en) 2016-04-08 2021-03-23 Mankind Pharma Ltd. GPR119 agonist compounds
JP7095288B2 (ja) * 2018-01-24 2022-07-05 富士フイルムビジネスイノベーション株式会社 定着装置および画像形成装置
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators
WO2025037213A1 (en) * 2023-08-11 2025-02-20 Mankind Pharma Ltd. Pharmaceutical formulations of gpr119 agonists and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003221386A (ja) * 2001-11-26 2003-08-05 Takeda Chem Ind Ltd 二環性誘導体、その製造法およびその用途
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
US20120016119A1 (en) * 2009-01-22 2012-01-19 Yasunori Tsuboi NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
TW201111361A (en) 2009-06-24 2011-04-01 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
US8431595B2 (en) * 2009-08-20 2013-04-30 The University Of Tennessee Research Foundation Furanopyridine cannabinoid compounds and related methods of use
CA2798610A1 (en) * 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
WO2011140161A1 (en) * 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011138427A2 (en) 2010-05-07 2011-11-10 Boehringer Ingelheim International Gmbh Pyridazinones as gpr119 agonists
UY33805A (es) * 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.

Also Published As

Publication number Publication date
AP2013006985A0 (en) 2013-07-31
CO6781501A2 (es) 2013-10-31
US20130018030A1 (en) 2013-01-17
SG192036A1 (en) 2013-08-30
BR112013017669A2 (pt) 2018-09-18
JP2014502988A (ja) 2014-02-06
MA34839B1 (fr) 2014-01-02
EP2665719A1 (en) 2013-11-27
EP2665719B1 (en) 2016-05-04
JP5703393B2 (ja) 2015-04-15
KR20140003496A (ko) 2014-01-09
AU2012208530A1 (en) 2013-07-11
PH12013501515A1 (en) 2013-09-16
CA2825124A1 (en) 2012-07-26
MX2013008083A (es) 2013-09-13
US8778926B2 (en) 2014-07-15
UY33871A (es) 2012-07-31
ECSP13012800A (es) 2013-10-31
EA201300846A1 (ru) 2013-12-30
CN103443097A (zh) 2013-12-11
WO2012098217A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
AR084905A1 (es) Derivados de 2,3-dihidro-furo[2,3-c]piridina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por la activacion del receptor gpr119 acoplado a proteinas g
AR084349A1 (es) Derivados de dihidro-pirano fusionados como moduladores de gpr119
AR086895A1 (es) Piperidinas sustituidas moduladoras de receptores gpr119, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de la diabetes, dislipidemias y obesidad
AR087913A1 (es) Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
AR078786A1 (es) Derivados de la cromenona
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
AR080057A1 (es) Piridinas disustituidas como anticancerigenos
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR080143A1 (es) Pirrolidina-2-carboxamidas sustituidas, composicion farmaceutica que las contiene y su uso en el tratamiento de tastornos oncologicos
AR076360A1 (es) Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer
AR094313A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
DOP2010000387A (es) Compuestos pirazolicos 436
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
AR097431A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
NI201100020A (es) NUEVOS DERIVADOS DE IMIDAZO[1,2-a] PIRIMIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACIÓN COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACIÓN PARTICULARMENTE COMO INHIBIDOR DE MET.
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
CR20170468A (es) Compuestos novedosos
AR097543A1 (es) COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO

Legal Events

Date Code Title Description
FB Suspension of granting procedure